Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729240 | 0.98 | HRH3 (0.53) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL845155 | 0.98 | HRH3 (0.52) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL27729397 | 0.96 | HRH3 (0.50) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL23113743 | 0.94 | HRH3 (0.47) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL27801847 | 0.93 | SMN1; SMN2 (0.49) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL27724955 | 0.91 | SMN1; SMN2 (0.46) | HRH3ALDH1A1SMN1; SMN2CYP2D6TDP1 | |
| SCHEMBL2476102 | 0.82 | SIGMAR1 (0.62) | HRH3ALDH1A1TDP1CYP2C19SIGMAR1 | |
| SCHEMBL62595 | 0.82 | HRH3 (0.53) | HRH3ALDH1A1SMN1; SMN2KDM4ESIGMAR1 | |
| SCHEMBL2964350 | 0.82 | MEN1 (0.53) | ALDH1A1KDM4ESIGMAR1POLB | |
| SCHEMBL61472 | 0.82 | MC4R (0.62) | ALDH1A1HRH4KDM4EPRMT6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| CN-103384668-A | Novel compounds and compositions for inhibiting NAMPT | FORMA THERAPEUTICS INC | 2013-11-06 | — | — | CN | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | claimed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-0180298-B1 | PYRIMIDINE COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-09-25 | — | — | EP | claimed |
| US-4808589-A | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-28 | — | — | US | claimed |
| EP-0134096-B1 | AMINOPYRIMIDINONE DERIVATIVES AS HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-01 | — | — | EP | claimed |
| US-4694008-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-09-15 | — | — | US | claimed |
| EP-0180298-A2 | Pyrimidine compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| EP-0169969-A2 | Sulphamoylguanidine derivatives | HOECHST UK LIMITED (GB) | 1986-02-05 | — | — | EP | claimed |
| EP-0159533-A2 | Thiatriazine derivatives | HOECHST UK LIMITED (GB) | 1985-10-30 | — | — | EP | claimed |
| EP-0134096-A2 | Aminopyrimidinone derivatives as histamine H2-antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-03-13 | — | — | EP | claimed |
| EP-0104611-A2 | Thiatriazine derivatives | HOECHST UK LIMITED (GB) | 1984-04-04 | — | — | EP | claimed |
| EP-0087274-A2 | Pyrimidone derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-08-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HRH3 1402/4885ALDH1A1 1273/4885SMN1; SMN2 1497/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HRH3 1402/4885ALDH1A1 1273/4885SMN1; SMN2 1497/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HRH3 1764/4885ALDH1A1 994/4885SMN1; SMN2 1001/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HRH3 1764/4885ALDH1A1 994/4885SMN1; SMN2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.